BJMO - 2021, issue SPECIAL, march 2021
dr. A. Padhani
In the same way that molecularly targeted therapies have transformed decision making of many diseases, advances in nuclear medicine and molecular imaging are poised to re-invent the way in which we diagnose, stage, and monitor response to therapy in patients with prostate cancer. Several next-generation imaging (NGI) modalities facilitate an improved diagnostic accuracy for the staging of prostate cancer, especially at lower tumour burdens. In view of these new imaging modalities, the American Society of Clinical Oncology (ASCO) recently formulated recommendations on how to appropriately use these techniques in different prostate cancer subgroups. During BMUC 2021, Prof. Anwar Padhani talked us through the key take home messages of these guidelines.
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
